Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell

Cisplatin resistance is an obstacle for the effective treatment of non-small cell lung cancer (NSCLC). The combined use of two or more chemotherapeutic agents displays advantages for the clinical treatment of drug-resistant lung cancer. The present study aimed to assess the synergy of the dual PI3K/...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hao, Shi, Yuhuan, Jiao, Xiuxiu, Yang, Gang, Wang, Rong, Yuan, Yongfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584016/
https://www.ncbi.nlm.nih.gov/pubmed/33123242
http://dx.doi.org/10.3892/ol.2020.12189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584016/
https://www.ncbi.nlm.nih.gov/pubmed/33123242
http://dx.doi.org/10.3892/ol.2020.12189

Ejemplares similares